Compare GE HealthCare Technologies Inc. Common Stock (GEHC) vs UiPath Inc (PATH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE HealthCare Technologies Inc. Common Stock vs UiPath Inc — how do they compare? GE HealthCare Technologies Inc. Common Stock trades at $68.66 (market cap $31.07B), while UiPath Inc trades at $12.92 (market cap $6.91B). The key difference: GE HealthCare Technologies Inc. Common Stock is far larger — about 4.5× UiPath Inc's market cap, and GE HealthCare Technologies Inc. Common Stock pays a 0.23% dividend while UiPath Inc pays none. Which is the better fit depends on your goals.
| GEHC | PATH | |
|---|---|---|
Market Cap | $31.07B | $6.91B |
Volume | 3,443,020 | 26,239,123 |
Sector | Health | Technology |
52-Week High | $88.16 | $19.29 |
52-Week Low | $59.48 | $9.38 |
Enterprise Value | $39.53B | $5.70B |
Dividend Yield | 0.23% | — |
Typical Hold Time | — | 139 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
UiPath (PATH) trades at $13.06, down 1.95% on the day, with a bullish technical signal from moving averages but neutral oscillators. Revenue growth is robust, increasing from $1.3B in 2024 to $1.43B in 2025, with a projected net profit of $362M in 2026. Recent news highlights expanded AI partnerships and raised guidance, though the stock faces near-term volatility.
The outlook is cautiously optimistic, with a consensus price target of $15.13 offering potential upside. Key opportunities include strong enterprise demand and AI monetization, while risks involve competitive pressures and execution challenges in achieving profitability targets. Analyst sentiment is mixed, with a majority hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →
